Latest filing published 14 Feb 2025 for X4 Pharmaceuticals, Inc.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Adam S. Mostafa is a declared insider of X4 Pharmaceuticals, Inc (finance chief), with filings sourced from SEC (Form 4). In total, 33 filings cover trades dated from 17 June 2019 to 12 February 2025.
On the market, this insider has only sold: 21 sales, €674k in total. The totals do not cover 5 filings with an undisclosed amount. Besides market trades, the filings include 12 share grants. In 2025 alone, the filings show no purchases and 1 sale.
The latest filing, published on 14 February 2025, reports a share grant in X4 Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations